Internship
Develops programmable cell therapies for cancer
No salary listed
San Bruno, CA, USA
Get referrals →
You have ways to get a ArsenalBio referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 5 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Arsenal Biosciences focuses on developing programmable cell therapies to treat solid tumor cancers. Their approach involves reprogramming cells to enhance their ability to fight cancer. The company is currently in the clinical stage, concentrating on research and development to bring these therapies to market. Unlike many competitors, Arsenal Biosciences emphasizes a diverse team of experts from various scientific and clinical backgrounds, which strengthens their ability to innovate in cancer treatment. Their goal is to create effective therapies that can be commercialized and made available to patients suffering from solid tumors.
Company Size
201-500
Company Stage
Series C
Total Funding
$630M
Headquarters
San Francisco, California
Founded
2019
Help us improve and share your feedback! Did you find this helpful?
Medical, dental, & vision coverage
Virtual & telehealth options
Parental leave
Flexible work schedule
Flexible PTO
Mental health resources
South San Francisco, Calif. - January 6, 2025 - Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Ken Drazan, M.D., ArsenalBio's CEO and Chairman, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025, at 4 p.m. PST.
Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Nate Hardy will join its management team as Chief Financial Officer, effective October 7, 2024.
ArsenalBio bags $325 million to develop crispr-engineered cell therapies.
Oversubscribed Series C welcomes multiple new investors South San Francisco, Calif. – September 4, 2024 – Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the close of an oversubscribed $325 million Series C financing round. The funding round included new […]
T. Rowe Price joins $325 million financing for ArsenalBio.